Vabrinty 45 mg/.375mL
Leuprolide acetate · INJECTION, SUSPENSION, EXTENDED RELEASE · URONOVA PHARMACEUTICALS, INC.
Vabrinty is a injection, suspension, extended release containing leuprolide acetate at 45 mg/.375mL, taken subcutaneous. Manufactured by URONOVA PHARMACEUTICALS, INC..
Key Facts
- Brand Name
- Vabrinty
- Generic Name
- Leuprolide acetate
- NDC Code (Product)
85043-045- Manufacturer
- URONOVA PHARMACEUTICALS, INC.
- Strength
- 45 mg/.375mL
- Dosage Form
- INJECTION, SUSPENSION, EXTENDED RELEASE
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- NDA021731
- Marketing Start
- 08/04/2025
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is Vabrinty used for?
Vabrinty contains Leuprolide acetate. It is a injection, suspension, extended release taken subcutaneous. Consult your doctor for specific uses.
Is Vabrinty a controlled substance?
Vabrinty is not classified as a controlled substance by the DEA.
What is the generic name for Vabrinty?
The generic name for Vabrinty is Leuprolide acetate. There are 9 other brand versions of Leuprolide acetate.
What is the NDC code for Vabrinty 45 mg/.375mL?
The NDC (National Drug Code) for Vabrinty 45 mg/.375mL is 85043-045, listed by URONOVA PHARMACEUTICALS, INC..